| API | Active pharmaceutical ingredient |
| COX-2 | Cyclooxygenase-2 |
| CRP | C-reactive protein |
| CTC | Tramadol–celecoxib cocrystal |
| CYP | Cytochrome P450 |
| DOR | δ-opioid receptor |
| ECL2 | Second extracellular loop |
| EM | Extensive (normal) metabolizer |
| ER | Extended-release |
| FDCs | Fixed-dose combinations |
| GPCR | G protein-coupled receptor |
| IL | Interleukin (e.g., IL-2, IL-6, IL-8) |
| IM | Intermediate metabolizer |
| KOR | κ-opioid receptor |
| LPS | Lipopolysaccharide |
| M1 | O-desmethyltramadol (primary active metabolite) |
| MOR | μ-opioid receptor |
| NET | Norepinephrine transporter |
| NK | Natural killer (cells) |
| NMR | Nuclear magnetic resonance |
| NRI | Norepinephrine reuptake inhibition |
| NSAIDs | Nonsteroidal anti-inflammatory drugs |
| PM | Poor metabolizer |
| 5-HT | Serotonin (5-hydroxytryptamine) |
| SAR | Structure–activity relationship |
| SERT | Serotonin transporter |
| SIOM | 7-spiroindanyloxymorphone |
| TM | Transmembrane (helix) |
| TNF | Tumor necrosis factor |
| UM | Ultrarapid metabolizer |